Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gross Profit: 2024

Historic Gross Profit for Monte Rosa Therapeutics (GLUE) over the last 1 years, with Dec 2024 value amounting to $75.6 million.

  • Monte Rosa Therapeutics' Gross Profit rose 38.54% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $181.5 million, marking a year-over-year change of. This contributed to the annual value of $75.6 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Gross Profit of $75.6 million as of FY2024.
  • Over the past 5 years, Monte Rosa Therapeutics' Gross Profit peaked at $75.6 million during FY2024, and registered a low of $75.6 million during FY2024.
  • Moreover, its 1-year median value for Gross Profit was $75.6 million (2024), whereas its average is $75.6 million.